Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...
pharmaphorum2d
Novartis’ COPD combo show benefits in switching from established drugs
Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...